Insights from WCLC24 by Sarah Waliany

The WCLC24 is taking place at the San Diego Convention Center from September 7 to 10, 2024.

The WCLC24 is organised by the International Association for the Study of Lung Cancer (IASLC). This major conference is gathering leading experts, researchers, and oncologists to present and discuss the latest advancements in lung cancer research, treatment, and personalized therapies, fostering collaborative efforts towards overcoming the challenges of lung cancer.

Sarah Waliany, Thoracic Oncology Fellow at Mass General Cancer Center, shared some insights from the conference.

Larotrectinib for patients with NTRK-rearranged lung cancer

So proud of my amazing mentor Jessica Lin for presenting updated efficacy, safety, and biomarker data for larotrectinib for patients with NTRK-rearranged lung cancer WCLC24.

IRC-ORR 66%, median PFS 22 mo, median OS 39 mo.

Acquired resistance in 5 of 13 patients with post-progression biopsies.

TRUSTII trial showing findings consistent with TRUSTI

Truly amazing to see so many studies expand treatment options for patients with ROS1-rearranged lung cancer.

Especially great that the global TRUSTII trial showed findings consistent with TRUSTI, with responses to taletrectinib in pretreated and TKI-naive patients and promising cerebral responses.

Congrats to Jeff Yang for WCLC24 Clifton F. Mountain Lectureship Award

Huge congrats to Jeff Yang, for WCLC24 Clifton F. Mountain Lectureship Award for Staging for his and his team’s amazing work using AI to improve our ability to predict risk of recurrence in patients with stage 1 lung cancer and help the general public understand lung cancer staging.

The WCLC24 quiz

Phenomenal panel flexes their muscles in a WCLC24 quiz show showcasing major developments in targeted therapies for lung cancer!

Amazing how far we have come in improving treatments for patients!

The immune microenvironment of SCLC

Huge thanks to Luis Paz-Ares and his collaborators for critical work studying the immune microenvironment of SCLC and bringing much-needed breakthroughs such as bispecific T-cell engager targeting DLL3 and CD3 tarlatamab into treatment landscape for extensive-stage SCLC!

For more updates on WCLC24, visit oncodaily.com